Literature DB >> 16510606

Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer.

Anthony Kong1, Pierre Leboucher, Russell Leek, Véronique Calleja, Stuart Winter, Adrian Harris, Peter J Parker, Banafshé Larijani.   

Abstract

Overexpression and mutation of epidermal growth factor receptors (EGFR) have been shown to be important in the prognosis of several cancers, including head and neck cancers. However, our inability to define the activation status of these and other receptors limits our ability to assess the importance of these pathways and to exploit effectively new molecularly targeted treatments directed at their catalytic activities. Here we describe the use of automated, high-throughput fluorescence lifetime imaging microscopy to measure EGFR autophosphorylation status by fluorescence resonance energy transfer (FRET) in head and neck tumors. We have correlated FRET efficiency with the clinical and survival data. The results from head and neck arrays show that high FRET efficiency is correlated with worsening disease-free survival but not with overall survival. This powerful tool could be exploited as a new independent quantitative prognostic factor in clinical decisions and cancer management.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510606     DOI: 10.1158/0008-5472.CAN-05-2994

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Fluorescence lifetime measurements and biological imaging.

Authors:  Mikhail Y Berezin; Samuel Achilefu
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer.

Authors:  James Keller; Kenneth R Shroyer; Shishir K Batajoo; Hong-Ling Zhao; Li Ming Dong; Michael J Hayman; Edward L Chan
Journal:  Cancer Invest       Date:  2010-09-27       Impact factor: 2.176

3.  Parallel visualization of multiple protein complexes in individual cells in tumor tissue.

Authors:  Karl-Johan Leuchowius; Carl-Magnus Clausson; Karin Grannas; Yücel Erbilgin; Johan Botling; Agata Zieba; Ulf Landegren; Ola Söderberg
Journal:  Mol Cell Proteomics       Date:  2013-02-22       Impact factor: 5.911

Review 4.  Molecular probes for fluorescence lifetime imaging.

Authors:  Pinaki Sarder; Dolonchampa Maji; Samuel Achilefu
Journal:  Bioconjug Chem       Date:  2015-05-22       Impact factor: 4.774

5.  Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

Authors:  R L Rego; N R Foster; T C Smyrk; M Le; M J O'Connell; D J Sargent; H Windschitl; F A Sinicrope
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

Review 6.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

7.  Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis.

Authors:  Shen Keren; Zhang Shoude; Zhao Lu; Yang Beibei
Journal:  Tumour Biol       Date:  2014-03

8.  Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.

Authors:  Miklós Petrás; Tamás Lajtos; Elza Friedländer; Almos Klekner; Eva Pintye; Burt G Feuerstein; János Szöllosi; György Vereb
Journal:  Neuro Oncol       Date:  2013-04-17       Impact factor: 12.300

Review 9.  EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.

Authors:  Laurie G Hudson; Natalie M Moss; M Sharon Stack
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

Review 10.  The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

Authors:  Muireann T Kelleher; Gilbert Fruhwirth; Gargi Patel; Enyinnaya Ofo; Frederic Festy; Paul R Barber; Simon M Ameer-Beg; Borivoj Vojnovic; Cheryl Gillett; Anthony Coolen; György Kéri; Paul A Ellis; Tony Ng
Journal:  Target Oncol       Date:  2009-09-16       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.